Know Cancer

forgot password

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

Phase 2
18 Years
Not Enrolling
Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer

Thank you

Trial Information

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the
efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free
survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced
patients with nonresectable or metastatic adenocarcinoma of the pancreas

Inclusion Criteria:

- Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic

- Chemotherapy naïve or chemotherapy experienced pancreatic cancer

Exclusion Criteria:

- Prior cancer vaccines or gene therapy

- History of clinically significant autoimmune disease (eg, systemic lupus
erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)

- History of another malignancy in the past five years, except adequately treated
non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of
the cervix, unless approved by the Medical Monitor

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:



United States: Food and Drug Administration

Study ID:




Start Date:

June 2002

Completion Date:

June 2004

Related Keywords:

  • Metastatic Pancreatic Cancer
  • Nonresectable Pancreatic Cancer
  • cancer vaccine
  • pancreatic cancer
  • metastatic pancreatic cancer
  • unresectable pancreatic cancer
  • immunotherapy
  • Pancreatic Neoplasms



Johns Hopkins University School of Medicine Baltimore, Maryland  21205
US Oncology Houston, Texas  77060